Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

2 No-Brainer Biotech Stocks to Buy Right Now

TheMotleyFool 
0 0 24.08.23
2 No-Brainer Biotech Stocks to Buy Right NowPhoto, wide shot, wide-angle lens, soft focus, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
 

Following the market's gloomy 2022, this year has been a breath of fresh air with the S 500 rising 14% so far in 2023. Some biotech stocks have soared even higher thanks to strong products. Cystic fibrosis specialist Vertex Pharmaceuticals (NASDAQ: VRTX) has risen 19% in 2023, while cancer specialist (NASDAQ: EXEL) has gained 31% -- and both medical areas are likely to see strong demand for a long time to come.

Let's see why these two stocks could make good additions to investors' portfolios now.

Image source: Getty Images.

Continue reading


Source Fool.com

Exelixis Inc. Stock

€46.29
0.830%
The Exelixis Inc. stock is trending slightly upwards today, with an increase of €0.38 (0.830%) compared to yesterday's price.
With 17 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
On the other hand, the target price of 43 € is below the current price of 46.29 € for Exelixis Inc., so the potential is actually -7.11%.
Show more
Like: 0
VRTX
Share

Comments

Not a member yet? Sign up for free!